ITMCTR2023000069尚未招募1 期
Based on PI3K/AKT/HIF-1 signaling pathway, to explore the clinical efficacy and mechanism of Zuoguiyin intervention in oxidative stress in the treatment of premature ovarian insufficiency
Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16 至 40（—）
- 性别
- Female
入选标准
- •(1) Meet the diagnostic criteria of premature ovarian insufficiency in accordance with the guidelines of the European Society of Human Reproduction and Embryology (ESHRE) and the Chinese Expert Consensus on the Clinical Diagnosis and Treatment of premature ovarian insufficiency in 2017;
- •(2) meet the TCM syndrome standard of kidney Yin deficiency;
- •(3) Those who are willing to sign informed consent and cooperate with research investigators.
- •(4) Patients who have not used any hormone drug therapy in the past 3 months and have no contraindications to hormone therapy;
排除标准
- •1) Pregnancy, abnormal reproductive tract development, complete androgen insensitivity syndrome, Asherman
- •Syndrome, polycystic ovary syndrome, thyroid disease, empty sella syndrome, central nervous system tumor, functional hypothalamic amenorrhea, ovarian resistance syndrome, etc.
- •(2) diabetes or abnormal blood sugar;
- •(3) Patients with heart, liver, spleen, lung, kidney, brain, blood, nervous, mental and other system diseases;
- •(4) Poor scientific research compliance and incomplete data;
- •(5) Patients who do not cooperate with the collection of physical type information.
研究者
相似试验
已完成
不适用
PI3K pathway analysis in tumor tissue and circulating DNA to obtain further insight in the efficacy of everolimus when combined with exemestane. A side-study protocol attached to standard treatment with everolimus and exemestane for postmenopausal patients with hormone receptor-positive advanced metastatic breast cancer, who have progressed on anastrozole or letrozoleadvanced metastatic breast cancer10006291breast cancerNL-OMON46855Vrije Universiteit Medisch Centrum175
进行中（未招募）
1 期
Analysis of tumor tissue and circulating genetic material in the blood to obtain further insight in the effectiveness of everolimus when combined with exemestane.A side-study protocol attached to standard treatment with everolimus and exemestane for postmenopausal patients with advanced metastatic breast cancer, who have progressed on anastrozole or letrozole.Hormone receptor-positive advanced metastatic breast cancer in postmenopausal patients who have progressed on anastrozole or letrozole.EUCTR2013-004120-11-NLVU University Medical Center175
招募中
不适用
Onderzoek naar kenmerken in tumorweefsel en bloed, die informatie kunnen geven over de werkzaamheid van everolimus in combinatie met exemestaaborstkanker, mammacarcinoom, gemetastaseerd, everolimus, exemestaan, biomarker.breast cancer, metastatic, everolimus, exemestane, biomarker.NL-OMON21846VU University Medical Center175
已完成
不适用
p-AKT Expression on Clinical Outcomes in Malignant LymphomaMalignant LymphomaP13K-AKT Pathway DeregulationNCT01789060Samsung Medical Center262
Unknown
不适用
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With ExemestaneHormone Receptor Positive Malignant Neoplasm of BreastMetastatic Breast CancerNCT02109913Amsterdam UMC, location VUmc175